On September 2, 2025 IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, reported that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York (Press release, IMUNON, SEP 2, 2025, View Source [SID1234655645]). During the conference, members of IMUNON’s management team will also be conducting in-person one-on-one meetings with investors September 8 – 10, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 27th Annual Global Investment Conference

Presentation available: Beginning Friday, September 5, 2025, 7:00 a.m. ET
Format: Pre-recorded webcast
Webcast: Here

The webcast will be available for 90 days at the link above or under the News & Investors tab of the Imunon website at www.imunon.com.